LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

12.6 -4.83

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.6

Máximo

13.53

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	4.989 49.8
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+51.29% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.3B
Apertura anterior	17.43
Cierre anterior	12.6

Noticias sobre sentimiento de mercado

By Acuity

50%

187 / 347 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 may 2026, 23:41 UTC

Ganancias

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 may 2026, 21:40 UTC

Ganancias

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 may 2026, 23:34 UTC

Charlas de Mercado

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 may 2026, 23:13 UTC

Ganancias

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 may 2026, 23:12 UTC

Ganancias

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 may 2026, 23:11 UTC

Ganancias

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 may 2026, 23:11 UTC

Ganancias

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 may 2026, 23:07 UTC

Ganancias

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 may 2026, 23:06 UTC

Ganancias

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 may 2026, 23:05 UTC

Ganancias

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 may 2026, 23:04 UTC

Ganancias

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 may 2026, 22:50 UTC

Ganancias

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 may 2026, 22:25 UTC

Charlas de Mercado

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 may 2026, 22:11 UTC

Ganancias

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 may 2026, 22:05 UTC

Charlas de Mercado

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 may 2026, 21:58 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:47 UTC

Charlas de Mercado

Ganancias

Costco Posts 13% Sales Growth in April -- Market Talk

6 may 2026, 21:46 UTC

Ganancias

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 may 2026, 21:40 UTC

Ganancias

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 may 2026, 21:35 UTC

Charlas de Mercado

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 may 2026, 21:32 UTC

Acciones populares

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 may 2026, 21:29 UTC

Ganancias

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

51.29% repunte

Estimación a 12 Meses

Media 20 USD 51.29%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

187 / 347 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.